Skip to content

US · ENGN · BIOTECHNOLOGY

enGene Holdings Inc. (ENGN) intrinsic value and stock valuation

$1.74as of 2026-11-21 · Mkt cap 92.15M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

enGene Holdings Inc. DCF and intrinsic value

InvestorsCraft values ENGN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ENGN’s statements →

enGene Holdings Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Montreal, QC H4R 2P1 engene.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-117.3M
20202025
Free cash flow
-$-100.72M
20202025
Total equity
$167.7M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-123.17M-$-62.3M-$-26.06M-$-19.43M-$-15.87M
Net income-$-117.3M-$-55.14M-$-99.92M-$-24.46M-$-23.44M
EPSd-$-2.29M-$-1.24M-$-4.24M-$-1.55M-$-1.48M
Operating cash flow-$-99.24M-$-48.28M-$-24.74M-$-17.59M-$-15.98M
Capital expenditure-$-1.49M-$-930K-$-320K-$-150K-$-250K
Free cash flow-$-100.72M-$-49.21M-$-25.06M-$-17.75M-$-16.23M
Total assets$221.5M$311.2M$87M$132M$131.5M
Total debt$31.8M$25M$9.78M$32.1M$4.16M
Net debt-$-18.36M-$-147.98M-$-71.74M-$-310K-$-1.07M
Total equity$167.7M$272.6M$72.5M$127.4M$127.4M
Cash and short-term investments$193.8M$238.4M$81.6M$310K$1.07M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$94.5M$38.3M$16.5M$15.5M$12.5M
Selling, general and administrative expenses$28.7M$24M$8.47M$3.26M$3.15M
Other expenses$0.00$0.00$1.13M$700K$250K
Operating expenses$123.2M$62.3M$26.1M$19.4M$15.9M
Cost and expenses$123.2M$62.3M$26.1M$19.4M$15.9M
Interest income$9.43M$10.4M$1.12M$130K$30K
Interest expense$2.99M$2.8M$4.95M$1.42M$5.02M
Depreciation and amortization$510K$320K$170K$240K$270K
Ebitda-$-113.8M-$-52.04M-$-94.77M-$-22.78M-$-18.14M
Operating income-$-123.17M-$-62.3M-$-26.06M-$-19.43M-$-15.87M
Total other income/expenses, net$5.86M$7.14M-$-73.84M-$-5.01M-$-7.57M
Income before tax-$-117.3M-$-55.16M-$-99.9M-$-24.44M-$-23.44M
Income tax expense$0.00-$-20K$20K$20K$0.00
Net income-$-117.3M-$-55.14M-$-99.92M-$-24.46M-$-23.44M
Weighted average shares outstanding$51.1M$44.6M$23.6M$15.8M$15.8M
Weighted average diluted shares outstanding$51.1M$44.6M$23.6M$15.8M$15.8M
Balance sheet
20252024202320222021
Cash and short-term investments$193.8M$238.4M$81.6M$310K$1.07M
Net receivables$2.23M$1.03M$2.34M$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$201.4M$247.4M$85.4M$510K$1.57M
Property, plant and equipment, net$10.2M$2.91M$590K$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$8.52M$59.5M$70K$131.5M$129.7M
Total non-current assets$20.1M$63.8M$1.52M$131.5M$129.9M
Total assets$221.5M$311.2M$87M$132M$131.5M
Accounts payable$6.69M$1.41M$1.16M$0.00$0.00
Short-term debt$10M$1.12M$560K$1.26M$1.05M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$32M$14.7M$5.26M$890K$330K
Long-term debt$21.8M$23.9M$9.22M$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$3.73M
Total non-current liabilities$21.8M$23.9M$9.22M$3.73M$3.73M
Capital lease obligations$6.46M$1.43M$0.00$0.00$0.00
Total liabilities$53.8M$38.6M$14.5M$4.62M$4.05M
Common stock$513.3M$509.8M$259.4M$131.5M$129.7M
Retained earnings-$-372.03M-$-254.73M-$-199.59M-$-4.11M-$-2.28M
Accumulated other comprehensive income (loss)-$-890K-$-1.42M-$-1.02M$0.00$0.00
Total equity$167.7M$272.6M$72.5M$127.4M$127.4M
Total investments$152.2M$124.9M$150K$131.5M$129.7M
Total debt$31.8M$25M$9.78M$32.1M$4.16M
Net debt-$-18.36M-$-147.98M-$-71.74M-$-310K-$-1.07M
Cash flow statement
20252024202320222021
Net income-$-117.3M-$-55.14M-$-99.92M-$-24.46M-$-23.44M
Depreciation and amortization$510K$320K$170K$240K$270K
Stock-based compensation$9.65M$5.32M$3.45M$120K$430K
Change in working capital$9.74M$100K-$-520K$2.17M-$-1.04M
Accounts receivable-$-590K$2.01M-$-1.01M$140K$290K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$4.94M$470K$370K-$-200K$110K
Net cash provided by operating activities-$-99.24M-$-48.28M-$-24.74M-$-17.59M-$-15.98M
Investments in property, plant and equipment-$-1.49M-$-930K-$-320K-$-150K-$-250K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-25.14M-$-125.95M-$-320K-$-150K-$-250K
Common stock issued$2.22M$260.2M$56.9M$10K$10K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.52M$265.7M$86.2M$28M$22.5M
Net change in cash-$-122.85M$91.5M$61.1M$9.42M$6.39M
Cash at end of period$50.2M$173M$81.5M$20.4M$11M
Operating cash flow-$-99.24M-$-48.28M-$-24.74M-$-17.59M-$-15.98M
Capital expenditure-$-1.49M-$-930K-$-320K-$-150K-$-250K
Free cash flow-$-100.72M-$-49.21M-$-25.06M-$-17.75M-$-16.23M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About enGene Holdings Inc.

        Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.

        CEO
        Ronald H. W. Cooper
        Employees
        82
        Beta
        -0.27

        Explore

        Frequently asked questions

        What is the intrinsic value of enGene Holdings Inc. (ENGN)?

        InvestorsCraft does not currently publish an intrinsic value for ENGN. How the IC value is calculated.

        Is ENGN undervalued?

        InvestorsCraft does not publish an undervaluation signal for ENGN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.